LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Atvērts

4.42 -7.92

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.37

Max

5.02

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+191.55% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-26M 229M
Iepriekšējā atvēršanas cena	12.34
Iepriekšējā slēgšanas cena	4.42

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. marts 23:12 UTC

Karstas akcijas

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

2026. g. 12. marts 22:15 UTC

Peļņas

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

2026. g. 12. marts 21:42 UTC

Galvenie ziņu notikumi

Stryker Says Cyberattack Disruption Is Continuing

2026. g. 12. marts 21:29 UTC

Galvenie ziņu notikumi

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

2026. g. 12. marts 21:27 UTC

Peļņas

Adobe CEO to Depart as AI Boosts Sales -- Update

2026. g. 12. marts 20:46 UTC

Peļņas

Adobe Posts Higher Sales With CEO Set to Depart

2026. g. 12. marts 20:21 UTC

Galvenie ziņu notikumi

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

2026. g. 12. marts 23:57 UTC

Tirgus saruna

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 12. marts 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. marts 23:38 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

2026. g. 12. marts 22:13 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 12. marts 22:13 UTC

Tirgus saruna

Peļņas

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

2026. g. 12. marts 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

2026. g. 12. marts 21:04 UTC

Peļņas

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q Sales $865M >WPM

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q Net $558.3M >WPM

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q EPS $1.23 >WPM

2026. g. 12. marts 20:57 UTC

Tirgus saruna

Galvenie ziņu notikumi

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

2026. g. 12. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 12. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. marts 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

2026. g. 12. marts 20:10 UTC

Peļņas

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

2026. g. 12. marts 20:05 UTC

Peļņas

Adobe 1Q Rev $6.4B >ADBE

2026. g. 12. marts 20:05 UTC

Peļņas

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

191.55% augšup

Prognoze 12 mēnešiem

Vidējais 14.14 USD 191.55%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.